MedPath

AvKare, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

353

FDA:353

Drug Approvals

Mirtazapine

Approval Date
May 20, 2025
FDA

Ondansetron

Approval Date
May 15, 2025
FDA

Oxybutynin Chloride

Approval Date
May 1, 2025
FDA

Captopril

Approval Date
Apr 22, 2025
FDA

Risperidone

Approval Date
Mar 19, 2025
FDA

Sildenafil

Approval Date
Apr 4, 2024
FDA

UREA

Approval Date
Apr 4, 2024
FDA

Liothyronine Sodium

Approval Date
Apr 4, 2024
FDA

Tizanidine Hydrochloride

Approval Date
Apr 4, 2024
FDA

Ranolazine

Approval Date
Mar 26, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 36
  • Next

Clinical Trials

No trials found

News

FDA Recalls Nearly 76,000 Cases of Eye Care Products Due to Manufacturing Deviations

The FDA has issued a recall for approximately 76,000 cases of over-the-counter ophthalmic products following an audit that revealed significant manufacturing deviations at BRS Analytical Services.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.